Compounds > bay h 2049
Page last updated: 2024-08-25

bay h 2049 and Adenocarcinoma

bay h 2049 has been researched along with Adenocarcinoma in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19903 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bissery, MC; Corbett, TH; Luk, GD; Mucci-LoRusso, P; Plowman, J; Polin, L; Valeriote, F1
Atassi, G; Dykes, DJ; Harrison, SD; Kabbe, HJ; Narayanan, VL; Paull, KD; Plowman, J; Yoder, OC1
Atassi, G; Dumont, P; Kabbe, HJ; Yoder, O1

Other Studies

3 other study(ies) available for bay h 2049 and Adenocarcinoma

ArticleYear
Activity of batracylin (NSC-320846) against solid tumors of mice.
    Investigational new drugs, 1989, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Intraductal, Noninfiltrating; Cell Survival; Cells, Cultured; Colonic Neoplasms; Drug Administration Schedule; Drug Screening Assays, Antitumor; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured

1989
Preclinical antitumor activity of batracylin (NSC 320846).
    Investigational new drugs, 1988, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation, Preclinical; Injections, Intraperitoneal; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred Strains; Quinazolines; Tumor Cells, Cultured

1988
A new antitumour agent, batracylin, selected by a preclinical solid tumour model.
    Drugs under experimental and clinical research, 1988, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Leukemia L1210; Leukemia P388; Melanoma, Experimental; Mice; Quinazolines

1988